首页/数据集/Dataset from A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease

Dataset from A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease

NIAID Data Ecosystem2026-05-10 收录

克罗恩病临床试验

单克隆抗体疗效评估

数据链接：

https://doi.org/10.25934/00004692 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.

应用场景：

创建时间：

2026-03-19

相关数据集

surrogate responses and sotrovimab

药物转录组学

单克隆抗体疗效评估

- accessions_metadata_nopatid.tsv contains the accession id, the day and treatment information - counts.tsv contains the tpm (transcripts per million) matrix for the respective accession ids.

Figshare2022-07-17 更新100

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome

干燥综合征药物临床试验

单克隆抗体疗效评估

This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome

DataCite Commons2025-12-16 更新20

Study on the efficacy evaluation of otolizumab in the treatment of refractory primary membranous nephropathy

难治性膜性肾病

单克隆抗体疗效评估

目的：回顾性观察奥比妥珠单抗（OBZ）治疗难治性原发性膜性肾病（pMN）的疗效和安全性。方法：分析2024年1月至2025年8月在内蒙古自治区人民医院接受OBZ治疗的21例难治性pMN患者的临床病理资料，包括基本信息、实验室指标、临床和免疫学结局、不良事件等。结果：本研究纳入了 21 名难治性 pMN 患者。在这21例患者中，18例（85.7%）达到临床缓解标准，其中3例（16.7%）达到完全

NIAID Data Ecosystem10

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

银屑病靶向治疗

单克隆抗体疗效评估

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

ChEBI2014-05-14 更新40

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn’s Disease

克罗恩病临床试验

难治性克罗恩病治疗

A Phase 2b study to evaluate the efficacy and safety of brazikumab (MEDI2070) in participants with moderate to severe Crohn’s disease who have failed or are intolerant to anti-tumor necrosis factor-al

NIAID Data Ecosystem20